Revenue of 109 million, verifies business profitability, Teda Biotech begins a new journey in AI-powered smart healthcare

How can AI Lynn Li’s international background accelerate the globalization of AI healthcare?

2025 is a critical year for TEDA Biotech’s strategic transformation. In the two announcements released on the evening of the 31st—one on annual performance and the other on management changes—it was revealed that the company has fully shifted its development focus to AI life and health business, completing the transition from a pure compound fertilizer supplier to a technology-driven AI enterprise.

According to disclosures, in 2025, the company recorded a revenue of 523 million RMB, an increase of 35.67% year-over-year. Among them, the company’s AI health and elderly care products and services generated 109 million RMB in revenue for the year, achieving profitability. At the same time, the company appointed Ms. Lynn Li as Co-CEO, responsible for the technological iteration, business expansion, and capital market strategy of the group’s “AI Medical Large Model MaaS Platform.” This laid a solid foundation for the long-term development of TEDA Biotech’s core AI track.

Full-stack technology system formed, AI healthcare business achieves leapfrog development

As the core driver of TEDA Biotech’s strategic transformation, the AI life and health business completed the construction of a full-stack technical architecture across hardware, data, models, and applications in 2025. A development pattern of technological independence, scenario industrialization, and ecosystem formation has been fully established, with key progress made in both core implementation and commercialization. On the hardware front, the company established a deep strategic partnership with Suihonghua, creating a safe, controllable, and elastically scalable domestically-produced heterogeneous computing power base, laying a hardware foundation for the continuous training, stable inference, and industrialization of AI medical large models.

Leveraging the full-stack technical advantages, the company’s AI medical large model MaaS platform successfully launched and operated in Xiamen and Yinchuan, achieving a critical upgrade from single-model applications to platform-based services. The platform centers on on-demand invocation and pay-as-you-go models, offering seven major model service sectors such as outpatient innovation, inpatient diagnosis and treatment, and medical insurance cost control. In practical applications, it has achieved over 30% reduction in outpatient waiting times and less than 5% error rate in medical record generation and modification—significantly promoting the equalization of high-quality medical capabilities and building a scalable profit model of “one-time development + continuous subscription,” realizing the dual transformation of technological and commercial value.

Welcoming the “Key Lady” of AI healthcare commercialization

The addition of Lynn Li, Co-CEO, injects strong momentum into the company’s AI healthcare transformation. This cross-industry leader with deep scientific research background, broad business acumen, international experience, and strategic resources will leverage her excellent experience in technological commercialization and global perspective to open up three strategic opportunities for TEDA Biotech: accelerating the commercialization of technological achievements, establishing sustainable profit models, and expanding globally.

Disclosed information shows that Ms. Lynn holds a Ph.D. in Chemistry from the University of Vienna and a Master’s in Management from Stanford Graduate School of Business. She has an outstanding track record in transforming cutting-edge medical technologies into commercial results and holds 163 patents and technology licenses worldwide.

This appointment will help TEDA Biotech optimize the technical pathway of the “Xihe No.1” medical large model and MaaS platform, promote large-scale application of AI capabilities in scenarios such as primary healthcare and medical insurance cost control, and address the industry’s “difficulties in landing AI medical solutions.” Moreover, Ms. Lynn’s international background is expected to lead the company’s AI business toward a globalized layout.

Summary

With an independently controllable full-stack technical foundation, clear and feasible commercialization models, and a comprehensive ecosystem partnership network, TEDA Biotech is accelerating its growth into a leading domestic AI medical large model MaaS operator. While empowering the intelligent upgrade of the healthcare industry, it also demonstrates long-term investment value with both growth potential and social impact to the capital market.

Looking ahead, TEDA Biotech will continue to focus on AI life and health business, unwaveringly promote the nationwide replication of its AI medical large model MaaS platform, and its transformation practice offers a replicable development path for traditional enterprises seeking industrial upgrading.